Male MS patients display lower levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone, with progressive MS males exhibiting more severe hypothalamic–pituitary-thyroid (HPT) axis dysfunction compared to RRMS males. This evidence concerns the gene PLOD1 and myeloid sarcoma.